The Global Market for Mesenchymal Stem Cells (MSCs) is Projected to Exceed US$7.2 Billion by 2022
Ability to Provide Targeted Delivery of Therapeutics
to Drive the Global Mesenchymal Stem Cells Market, According to a New Report by
Global Industry Analysts, Inc.
GIA launches comprehensive
analysis of industry segments, trends, growth drivers, market share, size and
demand forecasts on the global Mesenchymal Stem Cells (MSCs) market. The global market for Mesenchymal Stem Cells (MSCs) is
projected to exceed US$7.2 billion by 2022, driven by the rapidly aging population, rising incidence of chronic diseases,
government support in the form of favorable regulations and funding, and
increasing investments in stem cell-biology.
Mesenchymal Stem Cells (MSCs)
are gradually gaining therapeutic interest as they are increasingly considered
to have the potential to treat various degenerative and acute diseases. MSCs
are mainly used for replacing or repairing damaged tissues. Application of MSCs
in various therapeutic areas is largely due to the cells’ ability to
differentiate into a broad array of cells, and also due to their localization
properties. The cells have the ability to easily migrate to tissue injury or
tumor sites which helps in targeted delivery of therapeutic medication. Therapeutic
agents can be introduced precisely at the target sites with the help of MSC
gene therapies. MSCs have the potential to be used for releasing bioactive
molecules to stimulate recovery of injured cells. MSCs are additionally known
for their robust immunosuppressive properties because of which, they are
expected to be further exploited by researchers for developing heterologous as
well as autologous therapies for various diseases in the near future. The growth in the market is
benefiting from the rapidly aging population, rising incidence of chronic diseases, government support in the form of
favorable regulations and funding, and rising investments in the area of stem
cell-biology. MSCs are also being increasingly used for substituting operative
procedures such as knee-replacement surgeries. Collaborations and partnerships, and
increased emphasis on innovation constitute the key trends in the market. There
is also a growing interest in conducting further research on MSCs for exploring
their potential in tissue engineering as well as cellular therapy.
As stated by the new market
research report on Mesenchymal Stem Cells,
the United States represents the largest market worldwide. Asia-Pacific ranks
as the fastest growing market led by India and China. Large pool of patients who
can be treated with MSC therapies; increasing governmental support and funding
for popularizing MSC therapies as part of larger healthcare improvement
strategies; developing healthcare infrastructure; growing GDP, rising living
standards and higher healthcare spending represent major factors driving growth
in China and India.
Key players covered in the
report include Vericel Corporation, Cell Applications Inc., Celprogen Inc.,
Cyagen Biosciences Inc., MilliporeSigma, Genlantis Inc, Thermo Fischer
Scientific Inc., Lonza Group, Mesoblast Limited, Neuromics, Orthofix
International N.V, PromoCell GmbH., R&D Systems Inc., ScienCell Research
Laboratories, Stemcell Technologies Inc., Stemedica Cell Technologies Inc.
Trevigen Inc., and Vitro Biopharma, among others.
The research report titled "Mesenchymal Stem Cells (MSCs): A Global Strategic
Business Report" announced by
Global Industry Analysts Inc., provides a comprehensive review of the market,
industry overview, trends, growth drivers, latest product launches and recent
industry activity. The report provides market estimates and projections in US
dollars for major geographic markets including the United States, Canada,
Japan, Europe, Asia-Pacific, and Rest of World.
Global Industry Analysts,
Inc. 6150 Hellyer Ave., San Jose CA 95138, USA, All Rights Reserved.
Comments
Post a Comment